ReviewClinical and experimental medicine2024
Recent nanotheranostic approaches in cancer research.
Review in Clinical and experimental medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 87 citations in OpenAlex.
- 4D nanoimaging-guided smart therapeutics: spatiotemporal control of disease microenvironments.RSC advances · 2026Review
- Theranostic Smart Bionanosensors for Solid Tumors: Advances, Challenges, and Future Directions.Applied biochemistry and biotechnology · 2026Review
- Development and evaluation of glycine conjugated polypropyleneimine dendrimers for targeted chloroquine delivery.Discover nano · 2026Article
- Electrospun Fibrous Architectures for Localized Delivery of Photosensitizers in Cancer Therapy.Molecules (Basel, Switzerland) · 2026Article
- AI-driven nanomedicine for cancer theranostics.Molecular cancer · 2026Review
- Illumination of Targeting Nanotherapeutics with Precision Eyes: From Optical to Radio-nanotheranostics.Theranostics · 2026Review
- Synthesis and anticancer potential of glycosides.RSC advances · 2025Review
- Theranostics in the management of colorectal cancer.Discover nano · 2025Review
- Strategic Objectives of Nanotechnology-Driven Repurposing in Radiopharmacy-Implications for Radiopharmaceutical Repurposing (Beyond Oncology).Pharmaceutics · 2025Review
- Peptide-Based Nanoparticle for Tumor Therapy.Biomedicines · 2025Review
- Advancing the potential of nanoparticles for cancer detection and precision therapeutics.Medical oncology (Northwood, London, England) · 2025Review
- Review
- Advances in Materials Science for Precision Melanoma Therapy: Nanotechnology-Enhanced Drug Delivery Systems.Pharmaceutics · 2025Review
- Nano-Radiopharmaceuticals in Colon Cancer: Current Applications, Challenges, and Future Directions.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Emerging nanoplatforms towards microenvironment-responsive glioma therapy.Medical oncology (Northwood, London, England) · 2025Review
- Nanoparticles as Drug Delivery Carrier-synthesis, Functionalization and Application.Current pharmaceutical design · 2025Review
- Nanoparticles as Novel Drug Delivery Systems for Cancer Treatment: Current Status and Future Perspectives.Current pharmaceutical design · 2025Review
- Exploring two tumor treatment strategies: effectiveness of ribosome inactivating proteins and mesenchymal stem cells/MSC derived extracellular vesicles in cancer treatment.Frontiers in oncology · 2025Review
- Advances in Nanotheranostic Systems for Concurrent Cancer Imaging and Therapy: An Overview of the Last 5 Years.Molecules (Basel, Switzerland) · 2024Review
- Advancements in tantalum based nanoparticles for integrated imaging and photothermal therapy in cancer management.RSC advances · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Humanity is suffering from cancer which has become a root cause of untimely deaths of individuals around the globe in the recent past. Nanotheranostics integrates therapeutics and diagnostics to monitor treatment response and enhance drug efficacy and safety. We hereby propose to discuss all recent cancer imaging and diagnostic tools, the mechanism of targeting tumor cells, and current nanotheranostic platforms available for cancer. This review discusses various nanotheranostic agents and novel molecular imaging tools like MRI, CT, PET, SPEC, and PAT used for cancer diagnostics. Emphasis is given to gold nanoparticles, silica, liposomes, dendrimers, and metal-based agents. We also highlight the mechanism of targeting the tumor cells, and the limitations of different nanotheranostic agents in the field of research for cancer treatment. Due to the complexity in this area, multifunctional and hybrid nanoparticles functionalized with targeted moieties or anti-cancer drugs show the best feature for theranostics that enables them to work on carrying and delivering active materials to the desired area of the requirement for early detection and diagnosis. Non-invasive imaging techniques have a specificity of receptor binding and internalization processes of the nanosystems within the cancer cells. Nanotheranostics may provide the appropriate medicine at the appropriate dose to the appropriate patient at the appropriate time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.